TY - JOUR
T1 - Reticular dysgenesis-associated AK2 protects hematopoietic stem and progenitor cell development from oxidative stress
AU - Rissone, Alberto
AU - Weinacht, Katja Gabriele
AU - la Marca, Giancarlo
AU - Bishop, Kevin
AU - Giocaliere, Elisa
AU - Jagadeesh, Jayashree
AU - Felgentreff, Kerstin
AU - Dobbs, Kerry
AU - Al-Herz, Waleed
AU - Jones, Marypat
AU - Chandrasekharappa, Settara
AU - Kirby, Martha
AU - Wincovitch, Stephen
AU - Simon, Karen Lyn
AU - Itan, Yuval
AU - DeVine, Alex
AU - Schlaeger, Thorsten
AU - Schambach, Axel
AU - Sood, Raman
AU - Notarangelo, Luigi D.
AU - Candotti, Fabio
N1 - Publisher Copyright:
© This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
PY - 2015/7/27
Y1 - 2015/7/27
N2 - Adenylate kinases (AKs) are phosphotransferases that regulate the cellular adenine nucleotide composition and play a critical role in the energy homeostasis of all tissues. The AK2 isoenzyme is expressed in the mitochondrial intermembrane space and is mutated in reticular dysgenesis (RD), a rare form of severe combined immunodeficiency (SCID) in humans. RD is characterized by a maturation arrest in the myeloid and lymphoid lineages, leading to early onset, recurrent, and overwhelming infections. To gain insight into the pathophysiology of RD, we studied the effects of AK2 deficiency using the zebrafish model and induced pluripotent stem cells (iPSCs) derived from fibroblasts of an RD patient. In zebrafish, Ak2 deficiency affected hematopoietic stem and progenitor cell (HSPC) development with increased oxidative stress and apoptosis. AK2-deficient iPSCs recapitulated the characteristic myeloid maturation arrest at the promyelocyte stage and demonstrated an increased AMP/ADP ratio, indicative of an energy-depleted adenine nucleotide profile. Antioxidant treatment rescued the hematopoietic phenotypes in vivo in ak2 mutant zebrafish and restored differentiation of AK2-deficient iPSCs into mature granulocytes. Our results link hematopoietic cell fate in AK2 deficiency to cellular energy depletion and increased oxidative stress. This points to the potential use of antioxidants as a supportive therapeutic modality for patients with RD.
AB - Adenylate kinases (AKs) are phosphotransferases that regulate the cellular adenine nucleotide composition and play a critical role in the energy homeostasis of all tissues. The AK2 isoenzyme is expressed in the mitochondrial intermembrane space and is mutated in reticular dysgenesis (RD), a rare form of severe combined immunodeficiency (SCID) in humans. RD is characterized by a maturation arrest in the myeloid and lymphoid lineages, leading to early onset, recurrent, and overwhelming infections. To gain insight into the pathophysiology of RD, we studied the effects of AK2 deficiency using the zebrafish model and induced pluripotent stem cells (iPSCs) derived from fibroblasts of an RD patient. In zebrafish, Ak2 deficiency affected hematopoietic stem and progenitor cell (HSPC) development with increased oxidative stress and apoptosis. AK2-deficient iPSCs recapitulated the characteristic myeloid maturation arrest at the promyelocyte stage and demonstrated an increased AMP/ADP ratio, indicative of an energy-depleted adenine nucleotide profile. Antioxidant treatment rescued the hematopoietic phenotypes in vivo in ak2 mutant zebrafish and restored differentiation of AK2-deficient iPSCs into mature granulocytes. Our results link hematopoietic cell fate in AK2 deficiency to cellular energy depletion and increased oxidative stress. This points to the potential use of antioxidants as a supportive therapeutic modality for patients with RD.
UR - http://www.scopus.com/inward/record.url?scp=84964697743&partnerID=8YFLogxK
U2 - 10.1084/jem.20141286
DO - 10.1084/jem.20141286
M3 - Article
C2 - 26150473
AN - SCOPUS:84964697743
SN - 0022-1007
VL - 212
SP - 1185
EP - 1202
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 8
ER -